Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: Comparisons with general population

Current Opinion in HIV and AIDS

Volumn 11, Issue 5, 2016, Pages 492-500

  Wandeler, Gilles ^a,b,c   Johnson, Leigh F ^d   Egger, Matthias ^b,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Africa; antiretroviral therapy; Europe; HIV infection; life expectancy; North America

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AFRICA SOUTH OF THE SAHARA; CANADA; CD4 LYMPHOCYTE COUNT; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIFE EXPECTANCY; MALE; MORTALITY; PRIORITY JOURNAL; REVIEW; RWANDA; SEX DIFFERENCE; TREND STUDY; GLOBAL HEALTH; HIV INFECTIONS;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE;

EID: 84973092252     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000298     Document Type: Review

References (33)

1. UNAIDS. ?15 by 15?-A global target achieved. Geneva: 2015. http://www.unaids.org/en/resources/documents/2015/15-by-15-A-global-Target-Achieved. [Accessed 1 May 2016]
2. UNAIDS. 90-90-90-An ambitious treatment target to help end the AIDS epidemic j UNAIDS. Geneva: 2014: 1-33. http://www.unaids.org/en/resources/documents/2014/90-90-90. [Accessed 1 May 2016]
3. Avila D, Althoff KN, Mugglin C, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-middle-And high-income countries. J Acquir Immune Defic Syndr 2014; 65:e8-e16.
4. Koller M, Patel K, Chi BH, et al. Immunodeficiency in children starting antiretroviral therapy in low-middle-And high-income countries. J Acquir Immune Defic Syndr 2015; 68:62-72.
5. EggerM, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997; 315:1194-1199.
6. Farahani M, Price N, El-Halabi S, et al. Trends and determinants of survival for over 200000 patients on antiretroviral treatment in the Botswana National Program: 2002-2013. AIDS 2016; 30:477-485.
7. Sabin CA. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy? BMC Med 2013; 11:251.
8. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
9. Geng EH, Odeny TA, Lyamuya R, et al. Retention in care and patientreported reasons for undocumented transfer or stopping care among HIV-infected patients on antiretroviral therapy in Eastern Africa: application of a sampling-based approach. Clin Infect Dis 2016; 62:935-944.
10. Lima VD, Eyawo O, Ma H, et al. The impact of scaling-up combination antiretroviral therapy on patterns of mortality among HIVpositive persons in British Columbia, Canada. J Int AIDS Soc 2015; 18:20261.
11. Lloyd-Smith E, Brodkin E, Wood E, et al. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 2006; 20:445-450.
12. Patterson S, Cescon A, Samji H, et al. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis 2015; 15:274.
13. Guaraldi G, Cossarizza A, Franceschi C, et al. Life expectancy in the immune recovery era: the evolving scenario of the HIV epidemic in northern Italy. J Acquir Immune Defic Syndr 2014; 65:175-181.
14. May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011; 343:d6016.
15. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 2013; 10:e1001418.
16. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155:209-216.
17. Nsanzimana S, Remera E, Kanters S, et al. Life expectancy among HIVpositive patients in Rwanda: a retrospective observational cohort study. Lancet Glob Heal 2015; 3:e169-e177.
18. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8:6-13.
19. United Nations Department of Economic and Social Affairs. Population Division. World population prospects: the 2010 revision. 2011; 1-481.
20. Statistics Canada. Life tables, Canada, Provinces and Territories, 2009 to 2011. 2013. http://www.statcan.gc.ca/pub/84-537-x/84-537-x2013005-eng.htm. [Accessed 1 May 2016]
21. World Health Organization. Scaling up antiretroviral therapy in resourcelimited settings: guidelines for a public health approach. Geneva: World Health Organisation; 2002 ; 1-163. Available at: http://www.who.int/hiv/pub/prev-care/en/ScalingUp-E.pdf. [Accessed 1 May 2016]
22. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013; 1-269. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/978924150.5727-eng.pdf. [Accessed 1 May 2016]
23. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach-2010 revision. Geneva: World Health Organization; 2010; 1-194. Available at: http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html. [Accessed 1 May 2016]
24. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795-807; Available at: http://www.ncbi.nlm.nih.gov/pubmed/26192873. [Accessed 23 July 2015]
25. Government of Canada. HIV and AIDS in Canada: surveillance report to December 31, 2014. 2015. http://healthycanadians.gc.ca/publications/diseases-conditions-maladies-Affections/hiv-Aids-surveillance-2014-vih-sida/index-eng.php?page=8. [Accessed 1 May 2016]
26. Weber R, Huber M, Battegay M, et al. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort study. HIV Med 2015; 16:137-151.
27. Leprêtre A, Ba I, Lacombe K, et al. Prevalence and behavioural risks for HIV andHCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study. J Int AIDS Soc 2015; 18:19888.
28. Fox MP, Rosen S. Retention of adult patients on antiretroviral therapy in low-And middle-income countries. J Acquir Immune Defic Syndr 2015; 69:98-108.
29. Brinkhof MWG, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-Analysis. PLoS One 2009; 4:e5790.
30. Johnson LF, Dorrington RE, Laubscher R, et al. A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment. J Int AIDS Soc 2015; 18:20628.
31. Gueler A, Zwahlen M, Calmy A, et al. Getting there? Life expectancy by HIV status and education in Switzerland. Durban, South Africa, 18-22 July: 21st International AIDS Conference; 2016; Abstract A-792-0099-04072.
32. Egger M, MayM, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
33. Egger M, Johnson LF. Estimating trends in life expectancy in HIV-positive individuals. Lancet Glob Health 2015; 3:e122-e123.